Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.79 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.69 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.67 |
| ▸ | DRD2 | P14416 | 3/20 | 0.67 |
| ▸ | HTR1A | P08908 | 3/20 | 0.65 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.60 |
| ▸ | DRD4 | P21917 | 1/20 | 0.58 |
| ▸ | DRD3 | P35462 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | HRH1 | P35367 | 1/20 | 0.57 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.57 |
| ▸ | HTR7 | P34969 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10684565 | 1.00 | CYP2D6 (0.79) | CYP2D6KCNH2SIGMAR1DRD2HTR1A | |
| SCHEMBL5187793 | 0.89 | CYP2D6 (1.00) | CYP2D6KCNH2SIGMAR1DRD2HTR1A | |
| SCHEMBL9041083 | 0.87 | KCNH2 (0.80) | CYP2D6KCNH2SIGMAR1DRD2HTR1A | |
| Hydrochloric Acid SCHEMBL7986315 | 0.87 | CYP2D6 (0.96) | CYP2D6KCNH2SIGMAR1DRD2HTR1A | |
| SCHEMBL3025110 | 0.87 | CYP2D6 (0.90) | CYP2D6KCNH2SIGMAR1DRD2HTR1A | |
| SCHEMBL11355026 | 0.85 | CYP2D6 (0.87) | CYP2D6KCNH2SIGMAR1DRD2HTR1A | |
| SCHEMBL11250712 | 0.85 | CYP2D6 (0.87) | CYP2D6KCNH2SIGMAR1DRD2HTR1A | |
| Hydrochloric Acid SCHEMBL7971932 | 0.85 | CYP2D6 (0.87) | CYP2D6KCNH2SIGMAR1DRD2HTR1A | |
| SCHEMBL11242236 | 0.85 | CYP2D6 (0.87) | CYP2D6KCNH2SIGMAR1DRD2HTR1A | |
| SCHEMBL5988317 | 0.83 | KCNH2 (0.88) | CYP2D6KCNH2SIGMAR1DRD2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1971600-B1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2013-08-21 | — | — | EP | claimed |
| WO-2010008775-A1 | AMINOPYRIDOPYRAZINONE DERIVATIVES FOR TREATING NEURODEGENERATIVE DISEASES | LIGAND PHARMACEUTICALS INC. (US) | 2010-01-21 | — | — | WO | claimed |
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2009-05-21 | — | — | US | claimed |
| CN-122010947-A | Antagonists of adenosine A2a receptors | 阿道尔克斯治疗有限公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-3796900-B1 | TRITERPENE AMINE DERIVATIVES | DFH THERAPEUTICS (US) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024233922-A2 | PYRIDINE-PIPERAZINE-BASED SCAFFOLDS AS HIGHLY POTENT AND SELECTIVE NEUROLYSIN ACTIVATORS | TEXAS TECH UNIVERSITY SYSTEM (US) | 2024-11-14 | — | — | WO | disclosed |
| CN-115996929-A | Antagonists of adenosine A2a receptors | 阿道尔克斯治疗有限公司 | 2023-04-21 | — | — | CN | disclosed |
| EP-4146654-A1 | ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR | Adorx therapeutics Limited (GB) | 2023-03-15 | — | — | EP | disclosed |
| US-11236122-B2 | Triterpene amine derivatives | DFH THERAPEUTICS (US) | 2022-02-01 | — | — | US | disclosed |
| US-11236122-B2 | Triterpene amine derivatives | DFH THERAPEUTICS (US) | 2022-02-01 | — | — | US | disclosed |
| EP-3929203-A1 | DERIVATIVES OF AMPHOTERICIN B | Sfunga Therapeutics, Inc. (US) | 2021-12-29 | — | — | EP | disclosed |
| EP-0005142-A1 | Phenylpiperazine derivatives, process for their preparation, intermediates for this purpose and medicaments containing such phenylpiperazine derivatives | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1979-11-14 | — | — | EP | disclosed |
| US-4172834-A | ANALGESICS, ANTIHISTAMINES AND PSYCHOTROPIC AGENTS | STERLING DRUG INC. (US) | 1979-10-30 | — | — | US | disclosed |
| US-4152518-A | ANTIINFLAMMATORY AGENTS | STERLING DRUG INC. (US) | 1979-05-01 | — | — | US | disclosed |
| EP-0000220-A1 | Dihydrouracils, process for their preparation and pharmaceuticals containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-01-10 | — | — | EP | disclosed |
| US-4112105-A | Anti-inflammatory 3-(substituted-amino)-2,1-benzisothiazoles | STERLING DRUG INC. (US) | 1978-09-05 | — | — | US | disclosed |
| US-4062864-A | ANALGESIC, PSYCHOTROPIC, ANTIHISTAMINE | STERLING DRUG INC. (US) | 1977-12-13 | — | — | US | disclosed |
| US-4060526-A | 1-Heterocyclic alkyl-1,2,3,4-tetrahydroquinazolinones and analgesic intermediates thereof | PENNWALT CORPORATION (US) | 1977-11-29 | — | — | US | disclosed |
| US-3959309-A | ANALGESICS, PSYCHOTROPIC, ANTIHISTAMINE | STERLING DRUG INC. (US) | 1976-05-25 | — | — | US | disclosed |
| US-3948898-A | HYPOTENSIVES, SEDATIVES, ANTIARRHYTHMICS, BRADYCARDIACS | BOEHRINGER INGELHEIM GMBH (DT) | 1976-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236122-B2 | Triterpene amine derivatives | BET1, PGGT1B, NFATC1 | CYP2D6 1253/4885KCNH2 4582/4885SIGMAR1 1936/4885 |
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | WNT3A, WNT1, WNT3 | CYP2D6 928/4885KCNH2 3845/4885SIGMAR1 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.